CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...
Phase 3
Cleveland, Ohio, United States and 125 other locations
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...
Phase 3
Cleveland, Ohio, United States and 164 other locations
to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...
Phase 1, Phase 2
Cleveland, Ohio, United States and 33 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...
Phase 3
Cleveland, Ohio, United States and 23 other locations
to venetoclax + azacitidine in adults recently diagnosed with AML who are unable to be treated with intensive chemotherapy.Participants will...
Phase 2
Cleveland, Ohio, United States and 56 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...
Phase 2
Cleveland, Ohio, United States and 43 other locations
This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human ...
Phase 1, Phase 2
Cleveland, Ohio, United States and 14 other locations
). Both parts will be conducted in participants with previously untreated CD123+ AML who are ineligible for intensive chemotherapy....
Phase 2
Cleveland, Ohio, United States and 35 other locations
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (A...
Phase 1, Phase 2
Cleveland, Ohio, United States and 13 other locations
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SG...
Phase 1
Cleveland, Ohio, United States and 11 other locations
Clinical trials
Research sites
Resources
Legal